Further investigations to identify the receptor(s) for Wnt5A binding and other proteins involved in the downstream signaling via CaMKII in cell motility in prostate cancer will help to elucidate the novel role of CaMKII in the suppression of filopodia formation to increase cell motility in prostate cancer. This evidence concerns the gene WNT5A and prostate cancer.